bims-rebome Biomed News
on Rehabilitation of bone metastases
Issue of 2025–06–22
seven papers selected by
Alberto Selvanetti, Azienda Ospedaliera San Giovanni Addolorata



  1. Global Spine J. 2025 Jun 16. 21925682251352442
      Study DesignLiterature review with clinical recommendations.ObjectiveSpinal metastases represent a late complication of cancer and a major factor in decreased quality of life. The role of surgery for specific indications for spinal metastases is well established. Given the significant morbidity associated with spine surgery in this frail population, efforts are ongoing to decrease the surgical footprint. The objective of this study is to provide the readers with a concise curation of the latest spine literature on reducing the surgical footprint for spine metastases and clinical recommendations for how the practicing clinician should interpret and make use of this evidence.MethodsThe latest spine literature in the topic of reducing the surgical footprint for spine metastases was reviewed and clinical recommendations were formulated. The recommendations are dichotomously graded into strong and conditional based on the integration of scientific methodology and content expert opinion. This opinion considers experience and practical issues such as risks, burdens, costs, patient values, and circumstances.ResultsFour high impact studies were selected for review. The findings suggest that surgery plays a key role in improving patients' quality of life, but incidence of adverse events remains high and hence methods to decrease surgical morbidity are necessary. The integration of radiation into the treatment algorithm allows for less extensive surgical procedures and SBRT should be strongly considered after surgery for spine metastases in appropriate patient populations. Implementation of enhanced recovery after surgery (ERAS) protocols reduce perioperative morbidity for both open and minimally invasive surgeries and should be considered on an institutional level. Utilization of minimally invasive surgical stabilization should be considered as it results in fewer post operative complications, lower infection rates, less blood loss during surgery, and a shorter hospital stay compared to open stabilization of unstable pathology thoracolumbar fractures.ConclusionsThe role and benefits of surgery for metastatic spine disease are well established, yet surgery carries significant risk for adverse events which may negatively affect overall cancer care. Methods for reducing the surgical footprint include incorporation of stereotactic radiation allowing less extensive surgery, implementation of ERAS protocols and utilization of minimally invasive surgical strategies.
    Keywords:  enhanced recovery after surgery; frail; minimally invasive spine surgery; radiosurgery; spinal metases
    DOI:  https://doi.org/10.1177/21925682251352442
  2. Cureus. 2025 May;17(5): e84093
      Background This study aimed to examine the influence of wearing a corset with radiation therapy (RT) on pain, activities of daily living (ADL), and quality of life (QoL) in patients with thoracic or lumbar spinal bone metastases one month after RT. Methodology Fifty-two patients (24 males and 28 females) with thoracic or lumbar spinal bone metastases whose measurements were recorded at our institute between July 2012 and December 2016 were included in this study. Age, sex, ADL, pain, spinal instability, and QoL were investigated in our analyses. Patients were divided into stable (0-6 points) and unstable (7-18 points) groups based on their spinal instability neoplastic score. Patients in the stable and unstable groups performed early mobilization depending on their condition. The unstable group wore corsets. The corsets were soft and were worn for three months from the start of RT. Results The unstable group showed significant improvements in ADL and QoL and a significant reduction in pain one month after RT (P < 0.05). The stable group showed a significant improvement in QoL one month after RT (P < 0.05). Conclusions Corsets were effective for enabling early movement without lowering QoL in patients with spinal instability of thoracic or lumbar bone metastases.
    Keywords:  activities of daily living; corset; pain; radiation therapy; spinal bone metastases
    DOI:  https://doi.org/10.7759/cureus.84093
  3. Cureus. 2025 May;17(5): e84126
      Objective Denosumab (DEN)-related atypical femoral fracture (AFF) is a rare entity, and hence not feasible to examine with a single institution-based study. In light of this, we performed a retrospective analysis of the clinical characteristics of patients with metastatic bone tumors treated with DEN and developed AFF. Methods The Japanese Adverse Drug Event Report (JADER) database (2023.8 public version) from the second quarter of 2004 to the second quarter of 2023 was used to investigate the backgrounds of patients with metastatic bone tumors who developed AFF while receiving DEN. The time of AFF onset was defined as the number of days from the start of treatment to the onset of AFF. We also aimed to identify drugs associated with the development of AFF. Cut-off values for signal detection were χ2 ≥4 and number of reports ≥3. Results The JADER database contained 2,012 cases of metastatic bone tumors for which DEN was the suspect drug or administered concomitantly with the suspect drug. Of these cases, 106 (5.3%) had AFF, with 91 (85.8%) being women and 61 (57.5%) patients receiving drugs for osteoporosis. The duration from administration to the onset of AFF by DEN was known in 36 cases, and the median value was 926 [interquartile range (IQR): 534-1,552] days. Furthermore, among the drugs suspected of involvement other than DEN, a signal was detected for ZOL, with a reporting odds ratio (OR) of 6.93 and a 95% confidence interval (CI) of 4.39-10.93. Conclusions In JADER, AFF in patients with metastatic bone tumors receiving DEN was more common in women and patients receiving osteoporosis drugs, and the time of onset of AFF was approximately 2.5 years.
    Keywords:  adverse events; atypical femoral fracture; bisphosphonates; bone-modifying agents; denosumab; japanese adverse drug event report (jader) database; long-term efficacy; metastatic bone tumors; reporting odds ratio; zoledronic acid hydrate
    DOI:  https://doi.org/10.7759/cureus.84126
  4. Clin Orthop Relat Res. 2025 Jun 10.
    Multicenter Orthopaedic Tumor Research (MORTaR) Group
       BACKGROUND: Hip arthroplasty is often indicated in metastatic bone lesions of the proximal femur, with or without pathologic fracture. Conventional knowledge is that cemented fixation is best, although uncemented fixation has potential advantages of shorter operative time, avoidance of the physiologic stress of cement, and the chance for osseointegration. However, both techniques are options that are employed, and there is no clear evidence to guide this choice.
    QUESTIONS/PURPOSES: In patients with proximal femoral metastatic bone lesions who were carefully selected either to receive cemented or uncemented fixation based on patient age, bone quality, tumor histology type, and the anatomic location of the lesion, we asked: (1) What is the cumulative incidence of femoral stem revision and stem complication in patients treated with cemented and uncemented hip arthroplasty for proximal femoral metastatic bone disease? (2) Are perioperative radiation and uncemented fixation independently associated with stem complication?
    METHODS: Between January 2011 and December 2022, six centers performed 337 primary hip arthroplasties (THA or hemiarthroplasty) for proximal femoral metastatic bone disease. While these relative indications for fixation technique varied by center and surgeon, cemented fixation was used in some centers exclusively; where used selectively, it was generally used more frequently in older patients (> 65 years), any patient with poorer radiographic proximal femoral bone quality, or in the setting of pathologic fractures and/or lesions requiring intralesional resection rather than complete resection. Uncemented fixation was often selectively used in younger patients (< 65 years) with adequate radiographic proximal femoral bone quality and often for lesions where all macroscopically visible disease was removed with sufficient remaining bone to accept uncemented fixation. A total of 287 cemented reconstructions (of which 19% [55 of 287] were THAs and 81% [232 of 287] were hemiarthroplasties) and 50 uncemented reconstructions (of which 50% [25 of 50] were THAs and 50% [25 of 50] were hemiarthroplasties) were performed. A total of 66% (190 of 287) and 36% (18 of 50) of patients, respectively, had died before 2 years, and 21% (61 of 287) and 42% (21 of 50), respectively, were lost to follow-up before 2 years but were not known to have died. As expected, the groups were substantially different at baseline, with the uncemented group being younger, less likely to have had a pathologic fracture, more likely to have received attempted wide resection rather than intralesional resection, more likely to have received this fixation technique at certain centers, and more likely to have received a THA, indicating a generally better preoperative functional status. Because of those substantial baseline differences between the fixation groups, we did not compare them but rather will report each separately in terms of survivorship with respect to stem revision and stem complication and factors associated with stem complication in this retrospective study. Those lost before 2 years were included if they reached a study endpoint before being lost. Patients who underwent a resection of the proximal femur and proximal femoral replacement were not included. Femoral stem revision was defined as any femoral reoperation including femoral stem revision, femoral stem explant with or without spacer, fixation around the stem, and head-liner exchange for infection or dislocation. A stem complication was defined as aseptic loosening, periprosthetic fracture around the stem, stem breakage or fracture of the implant, or tumor recurrence around the stem. A patient with a stem complication did not have to undergo a reoperation to be included. Competing risk analysis was performed to estimate cumulative incidence (95% confidence interval [95% CI]) of femoral stem revision and stem complication, with death as a competing risk. Logistic regression assessed whether radiation or uncemented fixation were independently associated with stem complication when controlling for each other.
    RESULTS: In all patients, the cumulative incidence (considering death as a competing risk) of femoral stem revision at 2 years in the uncemented group was 4.4% (95% CI 0.8% to 13.6%) and 1.5% (95% CI 0.5% to 3.5%) in the cemented group. The cumulative incidence of stem complication at 2 years in the uncemented group was 2.0% (95% CI 0.2% to 9.4%) and 5.2% (95% CI 3.0% to 8.4%) in the cemented group. In patients who received radiation, the cumulative incidence (considering death as a competing risk) of femoral stem revision at 2 years in the uncemented group was 0% and 3.3% (95% CI 1.1% to 7.8%) in the cemented group. The cumulative incidence of stem complication at 2 years in the uncemented group was 0% and 7.8% (95% CI 3.8% to 13.6%) in the cemented group. We did not compare the groups statistically because they were so dissimilar at baseline. The percentage of patients who underwent femoral stem revision for periprosthetic fracture in the uncemented group was 2% (1 of 50) and 2% (6 of 287) in the cemented group. The percentage of patients who developed an inpatient venous thromboembolism in the uncemented group was 0% and 2.8% (8 of 287) in the cemented group; there was one patient with bone cement implantation syndrome in the cemented group. When controlling for each other, radiation (OR 1.6 [95% CI 0.7 to 3.9]; p = 0.30) and uncemented fixation (OR 0.2 [95% CI 0.01 to 1.2]; p = 0.17) were not independently associated with stem complication.
    CONCLUSION: Because of substantial baseline differences between our study groups (which reflect careful patient selection), we cannot say whether uncemented stems are equivalent to or superior to cemented stems. Fixation choice remains multifactorial based on patient age, bone quality, tumor histology, and the anatomic location of the lesion. These data suggest that cemented fixation remains a reliable option for all patients. However, this study found that for well-selected patients-generally those who were younger (< 65 years) with adequate radiographic proximal femoral bone quality and with lesions where all macroscopically visible disease was removed with sufficient remaining bone to accept uncemented fixation-uncemented stems can be a reasonable choice regardless of radiation status. Future comparative studies should focus on that subgroup of patients to see whether there are any specific advantages to uncemented reconstruction, such as shorter operative time, less physiologic stress of cement, and the chance for osseointegration, and if there are, whether those advantages come with any important tradeoffs.
    LEVEL OF EVIDENCE: Level III, therapeutic study.
    DOI:  https://doi.org/10.1097/CORR.0000000000003541
  5. J Oncol Pharm Pract. 2025 Jun 20. 10781552251350621
      ObjectiveThis review discusses current strategies, new advancements and clinical trials for the treatment of bone metastases.MethodWe performed a narrative review using literatures obtained from PubMed and Google Scholar using the terms such as "Prostate cancer", "bone metastases", "treatment". The search included articles between 2000 and 2024. For clinical trial information, we searched www.clincialtrial.gov and included trials of Prostate cancer and bone metastases.SummaryWe go through the mechanisms of action, clinical effectiveness, and limitations of current and emerging therapies, including bisphosphonates, Receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors, novel agents and Prostate-Specific Membrane Antigen (PSMA) targeted approaches. By examining recent research and ongoing clinical trials, we seek to inform the development of optimized treatment strategies and guide future research directions. The review discuss about novel agents such as Radium-223 and Lutetium-177. Lutetium-177 is emerging as a promising treatment for metastatic prostate cancer with bone involvement. These treatment options offer significant survival benefits in patients with bone-dominant metastatic prostate cancer. The review also explores combination treatments, where integrating bone-targeted therapies with systemic prostate cancer treatments holding potential for enhanced efficacy. Ongoing clinical trials investigating novel treatment options and advanced drug delivery techniques are highlighted.ConclusionThe advancements signify a promising direction in the treatment of bone metastases in prostate cancer, highlighting the need for continuous innovation to enhance patient care and outcomes.
    Keywords:  Prostate cancer; RANKL inhibitor; bisphosphonates; bone drug delivery; bone metastases
    DOI:  https://doi.org/10.1177/10781552251350621
  6. JCEM Case Rep. 2025 Aug;3(8): luaf121
      Denosumab is a frequently used medication, mainly for the treatment of osteoporosis and prevention of skeletal-related events in patients with metastatic cancer. However, the treatment can be associated with adverse events including hypocalcemia. We discuss the therapeutic challenges of denosumab-induced hypocalcemia in a patient with metastatic prostate adenocarcinoma. This 87-year-old patient presented to the emergency department after being found on the floor with altered mental status. Denosumab had been initiated 3 weeks earlier for stage 4 prostate adenocarcinoma with osteoblastic bone metastatic lesions. Blood analyses showed severe hypocalcemia (3.89 mg/dL [0.97 mmol/L]), which did not improve despite progressive incremental parenteral calcium administration and cholecalciferol supplementation. Management required 64 days of admission and titration of calcitriol. The patient was discharged after stabilizing plasma calcium level. Outpatient palliative care was later initiated because of progressive prostate adenocarcinoma, which ultimately led to the patient's death. Patients with metastatic bone disease, especially when treated with denosumab for prevention of skeletal-related events, present an increased risk of severe and even refractory hypocalcemia. More data are needed for optimal risk stratification of these patients, to identify robust predictors of hypocalcemia and to define the appropriate timing for starting calcium and vitamin D supplementation in high-risk individuals.
    Keywords:  denosumab; hypocalcemia; prostate adenocarcinoma and skeletal-related events
    DOI:  https://doi.org/10.1210/jcemcr/luaf121
  7. BMJ Support Palliat Care. 2025 Jun 17. pii: spcare-2024-005219. [Epub ahead of print]
       BACKGROUND: Pain is the second most prevalent symptom in patients with cancer after fatigue and is highly debilitating. There is an increasing emphasis on the prescription of non-pharmacological interventions, among which pain education is a prominent option. This study aimed to determine the effects of educational interventions on pain intensity and related outcomes in patients with oncological pain.
    METHODS: A systematic review was conducted following Cochrane and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, with registration in PROSPERO CRD42022343205 from searches in the main databases such as PubMed, Science Direct, Taylor and Francis, Cochrane (CENTRAL) and Scopus without language restriction, including randomised clinical trials and observational studies using the following keywords: "Pain Education" AND "Cancer". The PEDro (Physiotherapy Evidence Database scale) scale and MINORS (methodological index for non-randomised studies) criteria were used to analyse the risk of bias.
    RESULTS: 35 articles involving the use of educational interventions for patients with cancer pain were analysed in this study. Most protocols involved sessions implementing audiovisual aids, which the patient could easily access. The protocols showed significant results in terms of improvement in pain intensity, stress, quality of life and catastrophising in the intervened groups. Due to the heterogeneity of the interventions in the quantitative analysis, it was only possible to include six articles, which yielded significant results in improving pain (-0.65 (-1.18 to -0.12)).
    CONCLUSIONS: It is concluded that educational interventions can be effective in the treatment of cancer pain and should be considered as a complement to palliative care treatment.
    PROSPERO REGISTRATION NUMBER: CRD42022343205.
    Keywords:  Education and training; Pain; Palliative Care; Supportive care
    DOI:  https://doi.org/10.1136/spcare-2024-005219